Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001.

BRAF signaling and targeted therapies in melanoma.

Author information

1
Section of Cell and Molecular Biology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.

Abstract

The RAS/RAF/MEK/ERK signaling pathway has emerged as a major player in the induction and maintenance of melanoma, particularly the protein kinase BRAF, mutated in approximately 44% of melanoma cases. The availability of new drugs affecting the components of this pathway and pathways that may cooperate with MAPK signaling, means that targeted therapies are fast becoming a real option in the clinical management of melanoma. The authors discuss what they learned from clinical trials using first- and second-generation inhibitors to this pathway.

PMID:
19464601
DOI:
10.1016/j.hoc.2009.04.001
[Indexed for MEDLINE]

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center